American Society of Hematology Annual Meeting

Novel Drug Plus Rituxan May Serve as ‘New Treatment Option’ for Relapsed/Refractory Lymphoma Subset

December 13th 2021, 10:00pm

Article

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

December 13th 2021, 9:00pm

Article

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

Ninlaro-Darzalex Combo Elicits Favorable Treatment Outcomes, Responses in Newly Diagnosed Multiple Myeloma

December 13th 2021, 8:00pm

Article

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Patients With CLL Had Improved Quality of Life on Imbruvica Plus Rituxan

December 13th 2021, 2:30pm

Article

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Novel Treatment Combination Shows Promising Results, Tolerable Side Effects in Multiple Myeloma

December 12th 2021, 10:00pm

Article

Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone.

Kymriah May Be Safe and Effective in Children and Young Adults With Acute Lymphoblastic Leukemia Subtype

December 12th 2021, 5:11pm

Article

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021, 3:00pm

Article

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia

December 11th 2021, 10:00pm

Article

Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.

Imbruvica, Venclexta Combo Offers Chemotherapy-Free Regimen for Patients with CLL

December 11th 2021, 6:34pm

Article

Recent results demonstrated durable responses and no new side effects for Venclexta plus Imbruvica in pretreated chronic lymphocytic leukemia.

CAR-T Cell Therapy Bests Standard of Care in Health-Related Quality of Life for Patients With Lymphoma

December 11th 2021, 4:00pm

Article

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.